Genmab announces Phase II study of Daratumumab in smouldering multiple myeloma

Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. plans to start a Phase II study of daratumumab in smouldering multiple myeloma. The study (SMM2001) will evaluate three different dose schedules of daratumumab for the treatment of smouldering multiple myeloma. The study is expected to start enrolling patients in 2015.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Oncology Patient care CD38 monoclonal antibody daratumumab immunomodulatory agent Latest News smouldering multiple myeloma Source Type: news